Pollak, M N <br/><br/>
Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I.  [electronic resource] 

 -  Anticancer research   
 - 889-91 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0250-7005 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Arginine<br/>Breast Neoplasms--drug therapy<br/>Colonic Neoplasms--drug therapy<br/>Female<br/>Growth Hormone--blood<br/>Humans<br/>Insulin-Like Growth Factor I--analysis<br/>Kidney Neoplasms--drug therapy<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Octreotide--therapeutic use<br/>Ovarian Neoplasms--drug therapy<br/>Pancreatic Neoplasms--drug therapy<br/>Somatomedins--analysis